Latigo Biotherapeutics, Inc. LTGO
14.29 USD +0.96 (+7.23%)
Nov 11, 2026, 12:05 PM EST
13.36 Day range 14.35
12.60 52-week range 25.00
- YTD
- -21.68%
- 1 year
- -21.68%
- Market cap
- 951.40M
- EPS (ttm)
- -6.07
- Shares out
- 66.30M
- Forward P/E
- -7.44
- YTD return
- -21.68%
- 1-year return
- -21.68%
- Volume
- 58.52K
- Avg volume
- 295.88K
- Open
- 13.49
- Previous close
- 13.33
- Day's range
- 13.36 – 14.35
- 52-week range
- 12.60 – 25.00
- Analysts
- Strong Buy
- Price target
- 52.25 (+265.5%)
No chart data for this range yet.
Key statistics
- Enterprise value
- 1.31B
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 0.00
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- 0
- Total cash
- 55.00M
- Total debt
- 31.25M
- Return on equity
- 0.00%
- Short % of float
- 0.00%
- 50-day average
- 19.18
- 200-day average
- 19.18
Analyst view
Consensus: strong buy
Strong buy
Price target (mean) 52.25 +265.5% upside
Now 14.29
- Target (low)
- 36.00
- Target (mean)
- 52.25
- Target (high)
- 73.00
Ratings (0m) 4 4 buy · 0 hold · 0 sell
- Strong buy0
- Buy4
- Hold0
- Sell0
- Strong sell0
Next earnings
Consensus EPS estimate 0.00.
Financials — quick view
LTGO Revenue — quarterly 0
LTGO Net income — quarterly -20.95M
LTGO EPS — quarterly -0.55
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Sep 3, 2026 | Jun 30, 2026 | -0.61667 | -27.59 | -26.97 | -4,374.03% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Sep 1, 2026 | Leerink Partners | init | — | Outperform |
| Sep 1, 2026 | Jefferies | init | — | Buy |
| Sep 1, 2026 | Guggenheim | init | — | Buy |
About Latigo Biotherapeutics, Inc.
Latigo Biotherapeutics, Inc. develops non-opioid pain medicines designed to stop the transmission of pain without the risk of addiction. The company's pipeline includes LTG-001, an oral NaV1.8 inhibitor designed to provide fast-acting, opioid-sparing relief for the treatment of acute pain; LTG-321, a NaV1.8 inhibitor candidate developed for the treatment of chronic musculoskeletal pain, starting with osteoarthritis; and LTG-418, a NaV1.8 inhibitor developed for the treatment of acute and chronic pain. Latigo Biotherapeutics, Inc. was formerly known as WVB-Desmond, Inc. and changed its name to Latigo Biotherapeutics, Inc. in March 2019. Latigo Biotherapeutics, Inc. was incorporated in 2018 and is based in Thousand Oaks, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- latigobio.com
News
Latigo Biotherapeutics, Inc. (NASDAQ:LTGO) Stock Has Consensus Price Target of $52.25 According to Analysts 
Latigo Biotherapeutics Q3 EPS $(0.55) Beats $(0.58) Estimate 
Latigo Biotherapeutics Reports Third Quarter 2026 Financial Results and Recent Business Highlights 
Latigo Biotherapeutics Announces CEO Transition to Support the Company's Next Phase of Growth 
Latigo Biotherapeutics Q2 EPS $(27.59) Up From $(36.52) YoY, Sales $0.00, Same YoY 
Leerink Partners Initiates Coverage On Latigo Biotherapeutics with Outperform Rating, Announces Price Target of $36 
Jefferies Initiates Coverage On Latigo Biotherapeutics with Buy Rating, Announces Price Target of $50 
Guggenheim Initiates Coverage On Latigo Biotherapeutics with Buy Rating, Announces Price Target of $50 - Reported Earlier, Latigo Biotherapeutics Files To Sell Up To 16M IPO Shares Priced At $16-$18 Per Share
Your note
Sign in to keep a note on LTGO — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| 5AM VENTURES VI, L.P. | Beneficial Owner of more than 10% of a Class of Security | Conversion of Exercise of derivative security | Aug 9, 2026 | 0 |
| FORESITE CAPITAL MANAGEMENT V, LLC. | Beneficial Owner of more than 10% of a Class of Security | Purchase | Aug 9, 2026 | 0 |
| SANOFI SA | Beneficial Owner of more than 10% of a Class of Security | Conversion of Exercise of derivative security | Aug 9, 2026 | 0 |
| SEIDENBERG BETH C | Director and Beneficial Owner of more than 10% of a Class of Security | Conversion of Exercise of derivative security | Aug 9, 2026 | 0 |
| TANANBAUM JAMES B | Director and Beneficial Owner of more than 10% of a Class of Security | Purchase | Aug 9, 2026 | 0 |
| WESTLAKE BIOPARTNERS FUND I, L.P. | Beneficial Owner of more than 10% of a Class of Security | Conversion of Exercise of derivative security | Aug 9, 2026 | 0 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fidelity Contrafund | 1.42% | 940,228 | 14.61M | Aug 30, 2026 |
| Fidelity Select Portfolios-Select Biotechnology Portfolio | 0.72% | 480,316 | 7.46M | Aug 30, 2026 |
| Fidelity Select Portfolios-Select Health Care Portfolio | 0.32% | 212,500 | 3.30M | Aug 30, 2026 |
| Fidelity Contrafund-Fidelity Contrafund K6 | 0.30% | 199,400 | 3.10M | Aug 30, 2026 |
| Fidelity Advisor Series VII-Fidelity Advisor Biotechnology Fund | 0.29% | 191,400 | 2.97M | Aug 30, 2026 |
| Fidelity Advisor Series VII-Fidelity Advisor Health Care Fund | 0.16% | 105,200 | 1.63M | Aug 30, 2026 |